Histogenics’ (NASDAQ:HSGX) “Buy” Rating Reaffirmed at HC Wainwright

Histogenics (NASDAQ:HSGX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Tuesday, November 21st. They currently have a $3.50 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 81.35% from the company’s current price.

HSGX has been the topic of a number of other reports. Zacks Investment Research lowered Histogenics from a “buy” rating to a “hold” rating in a research note on Saturday, September 9th. ValuEngine lowered Histogenics from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $4.00 price target on shares of Histogenics in a research note on Friday, August 11th.

Histogenics (HSGX) traded up $0.01 during trading on Tuesday, hitting $1.93. The stock had a trading volume of 20,577 shares, compared to its average volume of 132,493. Histogenics has a 1-year low of $1.45 and a 1-year high of $2.40.

Histogenics (NASDAQ:HSGX) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. sell-side analysts anticipate that Histogenics will post -0.99 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/07/histogenics-corporation-hsgx-given-buy-rating-at-hc-wainwright.html.

About Histogenics

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply